Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Forte Biosciences

- PMLiVE

Dermavant reports positive late-stage results for Vtama cream in atopic dermatitis

The inflammatory skin disease affects up to 10% of adults and 20% of children worldwide

- PMLiVE

Eli Lilly shares positive late-stage results for lebrikizumab in atopic dermatitis

The study evaluated lebrikizumab in patients with moderate-to-severe AD and darker skin tones

- PMLiVE

Sanofi shares promising results for amlitelimab in moderate-to-severe atopic dermatitis

Amlitelimab could potentially offer treatment for a range of other immune-mediated diseases and inflammatory disorders

- PMLiVE

Almirall and CRG partner to advance therapeutic approaches for atopic dermatitis

The inflammatory skin disease currently affects an estimated 4.4% of adults in the EU

- PMLiVE

Sanofi/Regeneron’s Dupixent gets US label update for atopic dermatitis

Dupixent’s label now includes data supporting its use in hand and foot atopic dermatitis

- PMLiVE

Dermavant reports positive phase 3 results for Vtama cream in atopic dermatitis

More than 26 million people in the US are affected by the inflammatory skin disease

- PMLiVE

Almirall granted EC approval for Ebglyss in moderate-to-severe atopic dermatitis

The inflammatory skin disease currently affects an estimated 4.4% of adults in the EU

- PMLiVE

Eli Lilly and Almirall’s lebrikizumab shows sustained improvements in atopic dermatitis

The IL-13 inhibitor improved the symptoms of atopic dermatitis for up to two years

- PMLiVE

Almirall receives CHMP recommendation for lebrikizumab in atopic dermatitis

The drug has been recommended as a treatment option for adult and adolescent patients

- PMLiVE

World Atopic Eczema Day 2023: Almirall unveils awareness campaign

The inflammatory skin disease is estimated to affect 4.4% of adults in the EU

- PMLiVE

Incyte shares positive results for Opzelura cream in children with atopic dermatitis

Two to three million children aged two to 11 years in the US are affected by atopic dermatitis

- PMLiVE

Sanofi’s amlitelimab shows promise in phase 2b atopic dermatitis trial

The inflammatory skin disease affects an estimated 16.5 million adults in the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links